Publications by authors named "J Chin-Hon"
Article Synopsis
- The 2021 ISTH guidelines recommend standard doses of apixaban and rivaroxaban without considering BMI, but this study aims to compare the safety and efficacy of these DOACs and warfarin in underweight and obese patients.
- Out of 2940 patients, 492 were eligible, with the majority being either underweight (80) or obese (412), and the study used various statistical methods to analyze thromboembolic and bleeding events among the anticoagulant treatments.
- The results indicated that apixaban had significantly lower rates of venous thromboembolism and overall bleeding compared to warfarin, suggesting that patients with extreme body weights could benefit from DOAC therapy,
Macrophage activation syndrome is a life-threatening syndrome of uncontrolled immune activation with variable clinical presentation making early diagnosis difficult. It is often manifested by the development of multi-organ failure due to systemic inflammatory response. Patients with ulcerative colitis (UC) on purine antimetabolites are at high risk for severe myelosuppression due to the mechanism of thiopurine toxicity which potentially contributes to the development of macrophage activation syndrome.
View Article and Find Full Text PDF